专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014072500A1 TNT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
标题翻译：基于TNT的PAROXYSMAL ATRIAL FIBRILLATION的诊断
公开(公告)号：WO2014072500A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073476
申请日：2013-11-11
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6869 , G01N33/6887 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being susceptible to anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种诊断近期阵发性房颤的方法。该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（来自受试者的样品中的胰岛素样生长因子结合蛋白7）以及由此确定的量与参考量（参考量）的比较。此外，本发明涉及用于鉴定易于抗凝治疗的受试者的方法。进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

2. 发明申请

WO2014040759A1 IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
标题翻译：鉴别患有异常分娩的患者
公开(公告)号：WO2014040759A1
公开(公告)日：2014-03-20
申请号：PCT/EP2013/056706
申请日：2013-03-28
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
发明人： BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
摘要翻译：本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s）具有参考量（参考量）。本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

3. 发明申请

WO2015028469A2 MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
标题翻译：心脏失败症状治疗的标记标记
公开(公告)号：WO2015028469A2
公开(公告)日：2015-03-05
申请号：PCT/EP2014/068090
申请日：2014-08-26
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , BRUNNER, Hanspeter , DIETERLE, Thomas , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , BRUNNER, Hanspeter , DIETERLE, Thomas , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
摘要： The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
摘要翻译：本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白）从病人。进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。该方法还基于至少一种上述标记的水平的测量。

4. 发明申请

WO2014086833A1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 审中-公开
标题翻译：生物标志物选择心脏失败的治疗方法
公开(公告)号：WO2014086833A1
公开(公告)日：2014-06-12
申请号：PCT/EP2013/075491
申请日：2013-12-04
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
发明人： ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4745 , G01N2333/475 , G01N2333/705 , G01N2800/325 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, PlNP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.
摘要翻译：本发明涉及一种用于鉴定有资格给予选自β-阻滞剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统抑制剂的至少一种药物的受试者的方法。该方法基于选自GDF-15（生长分化因子15），内皮抑素，mimecan，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，PlNP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。此外，该方法包括将所确定的量与参考量进行比较的步骤。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。本发明还涉及用于鉴定合适的给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。

5. 发明申请

WO2014072471A1 NTPROBNP AND CTNT BASED THERAPY GUIDANCE IN HEART FAILURE 审中-公开
标题翻译： NTPROBNP和CTNT基于心脏失败的治疗指导
公开(公告)号：WO2014072471A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073399
申请日：2013-11-08
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , BRAZ, Julian , BRUNNER, Hans-Peter , CREEDEN, James , LOYDA, Hans-Jürgen , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian
发明人： BLOCK, Dirk , BRAZ, Julian , BRUNNER, Hans-Peter , CREEDEN, James , LOYDA, Hans-Jürgen , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种在患有心力衰竭的受试者中引导心力衰竭治疗的方法。该方法基于来自所述受试者的样品中BNP型肽和心肌肌钙蛋白的量的测定。本发明进一步设想的是适用于实施本发明的试剂盒和装置。本发明还涉及用于指导本文公开的患有心力衰竭的受试者的心力衰竭治疗的系统以及用于执行本文公开的方法的试剂和试剂盒。

6. 发明申请

WO2010124821A1 USE OF ENDOSTATIN AS A MARKER OF HEART FAILURE 审中-公开
标题翻译：内分泌作为心脏失败的标志物的使用
公开(公告)号：WO2010124821A1
公开(公告)日：2010-11-04
申请号：PCT/EP2010/002513
申请日：2010-04-23
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HUEDIG, Hendrik
发明人： WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HUEDIG, Hendrik
IPC分类号： G01N33/50 , G01N33/53
CPC分类号： G01N33/6887 , G01N2333/515 , G01N2333/58 , G01N2333/78 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in an individual comprising the steps of a) measuring in a sample obtained from the individual the concentration of the marker endostatin, of b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. Also disclosed are the use of endostatin as a marker protein in the assessment of heart failure, a marker combination comprising endostatin and a kit for measuring endostatin.
摘要翻译：本发明涉及一种用于评估个体心脏衰竭的方法，包括以下步骤：a）在从个体获得的样品中测量标记物内皮抑素的浓度，b）任选地在样品中测量一种或多种其他标记物的浓度以及通过将步骤（a）中确定的浓度与步骤（b）中确定的浓度（可选地）相比，在对照样品中确定的该标记物或这些标记物的浓度进行比较来评估心力衰竭。还公开了在评估心力衰竭中使用内皮抑素作为标记蛋白，包含内皮抑素的标记物组合和用于测量内皮抑素的试剂盒。

7. 发明申请

WO2008089994A1 USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译： IGFBP-7在心力衰竭评估中的应用
公开(公告)号：WO2008089994A1
公开(公告)日：2008-07-31
申请号：PCT/EP2008/000576
申请日：2008-01-25
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , EMILI, Andrew , FONG, Vincent , GRAMOLINI, Anthony , HESS, Georg , HEUDIG, Hendrik , ISSERLIN, Ruth , KISLINGER, Thomas , LIU, Peter , MACLENNAN, David , VON DER ELTZ, Herbert
发明人： WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , EMILI, Andrew , FONG, Vincent , GRAMOLINI, Anthony , HESS, Georg , HEUDIG, Hendrik , ISSERLIN, Ruth , KISLINGER, Thomas , LIU, Peter , MACLENNAN, David , VON DER ELTZ, Herbert
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/325 , G01N2800/56
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
摘要翻译：本发明涉及用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物IGFBP-7的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，并且通过比较在IGFBP-7中测定的浓度和为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记物的浓度进行比较来评估心力衰竭。还公开了在评估心力衰竭中使用IGFBP-7作为标记蛋白，包括IGFBP-7的标记组合和用于测量IGFBP-7的试剂盒。

8. 发明申请

WO2011012268A8 USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
公开(公告)号：WO2011012268A8
公开(公告)日：2011-02-03
申请号：PCT/EP2010/004521
申请日：2010-07-23
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , BLOCK, Dirk , ARAB, Sara , HESS, Georg , HUEDIG, Hendrik , LIU, Peter , WIENHUES-THELEN, Ursula-Henrike
发明人： BLOCK, Dirk , ARAB, Sara , HESS, Georg , HUEDIG, Hendrik , LIU, Peter , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker mimecan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for mimecan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan and a kit for measuring mimecan.

9. 发明申请

WO2012025355A1 USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开
标题翻译：生物标记在评估从早期转移到心脏失效的早期转换中的应用
公开(公告)号：WO2012025355A1
公开(公告)日：2012-03-01
申请号：PCT/EP2011/063398
申请日：2011-08-03
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HÜDIG, Hendrik , VOGEL-ZIEBOLZ, Sabine , BÖHM, Christine , HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
发明人： WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HÜDIG, Hendrik , VOGEL-ZIEBOLZ, Sabine , BÖHM, Christine , HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/53
CPC分类号： G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a method of diagnosing functional and/or structural abnormalities of the heart preceding heart failure, in a subject bearing risk factors of developing heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) assessing functional and/or a structural abnormalities by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The present invention also relates to a method of predicting the risk of a subject bearing risk factors of developing heart failure, to suffer from heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) predicting the risk of the subjects to suffer from heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The method, further characterized in that said one or more other marker is selected from the group consisting of a cardiac troponin marker, GDF 15 and insulin growth factor binding protein 7 (IGFBP7). In a preferred embodiment of the present invention, the subject suffers from left ventricular diastolic dysfunction. The present invention also relates to a method of deciding on the treatment of a subject bearing risk factors of developing heart failure and a method of monitoring the treatment. In preferred embodiments of the present invention, at least one further marker selected from: a cardiac troponin, GDF15 and IGFBP7. The present invention further relates to a method of monitoring treatment of functional and/or structural abnormalities of the heart preceding heart failure in a subject, the method comprising the steps of a) repeatedly determining, within given time intervals, the concentration of at least one cardiac troponin in at least one sample of said subject, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample, and c) assessing, based on the differences in the determined concentrations in one or more of the above-cited markers, whether the subject has undergone a change in its pathophysiological state.
摘要翻译：本发明涉及诊断患有心力衰竭的心脏的功能和/或结构异常的方法，所述方法包括以下步骤：a）在从个体获得的样品中测量，至少一种心肌肌钙蛋白的浓度，b）任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，和c）通过比较步骤（a）中测定的浓度来评估功能和/或结构异常）和任选地在步骤（b）中测定的浓度相对于在对照样品中确定的该标志物或这些标记物的浓度。本发明还涉及一种预测患有心力衰竭发生危险因素的受试者患有心力衰竭的风险的方法，所述方法包括以下步骤：a）在从个体获得的样品中测量至少至少一种心肌肌钙蛋白，b）任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，以及c）通过比较步骤（a）中测定的浓度来预测受试者患有心力衰竭的风险，和任选的步骤（b）中测定的浓度与对照样品中确定的该标志物或这些标记物的浓度。该方法的特征还在于所述一种或多种其它标志物选自心肌肌钙蛋白标志物，GDF15和胰岛素生长因子结合蛋白7（IGFBP7）。在本发明的优选实施方案中，受试者患有左心室舒张功能障碍。本发明还涉及一种决定患有心脏衰竭发展危险因素的受试者的治疗方法和一种监测治疗方法。在本发明的优选实施方案中，至少一种选自以下的标记物：心肌肌钙蛋白，GDF15和IGFBP7。本发明还涉及一种监测受试者心脏衰竭前心脏的功能和/或结构异常的治疗方法，所述方法包括以下步骤：a）在给定的时间间隔内重复确定至少一个所述对象的至少一个样品中的心肌肌钙蛋白b）任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，和c）将步骤（a）中测定的浓度和任选的浓度（（b）中测定的对照样品中确定的该标志物或这些标记物的浓度，以及c）基于一种或多种上述标记物中确定的浓度的差异来评估，受试者的病理生理状态发生变化。

10. 发明申请

WO2010043393A1 USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译：大智慧在评估心脏失败时的使用
公开(公告)号：WO2010043393A1
公开(公告)日：2010-04-22
申请号：PCT/EP2009/007399
申请日：2009-10-15
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , WIENHUES-THELEN, Ursula-Henrike , ARAB, Sara , BLOCK, Dirk , EMILI, Andrew , GRAMOLINI, Anthony , HESS, Georg , HUEDIG, Hendrik , LIU, Peter , MACLENNAN, David
发明人： WIENHUES-THELEN, Ursula-Henrike , ARAB, Sara , BLOCK, Dirk , EMILI, Andrew , GRAMOLINI, Anthony , HESS, Georg , HUEDIG, Hendrik , LIU, Peter , MACLENNAN, David
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4722 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.
摘要翻译：本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物双糖链球蛋白的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，以及通过比较测定双糖链聚糖中确定的浓度和将任选的一种或多种其它标记确定的浓度与参考群体中确定的该标记或这些标记的浓度进行比较来评估心力衰竭。还公开了使用双糖链蛋白作为评估心力衰竭的标记蛋白，包括双糖链蛋白聚糖和用于测量双糖链球蛋白的试剂盒的标记组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式